関連する実験動画

Updated: May 18, 2026

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

A2Aアデノシン受容体のコレステロール相互作用部位の予測

Ji Young Lee¹, Edward Lyman

¹Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA.

Journal of the American Chemical Society

|September 26, 2012

まとめ

分子ダイナミクスシミュレーションにより,アデノシンA2A受容体のコレステロール結合部位が明らかになりました. これらの相互作用は,受容体の機能に不可欠であり,細胞外および細胞内領域の両方で特定され,最近の研究された構造データによって1つのサイトが検証されました.

科学分野:

バイオケミストリーバイオケミストリー
分子生物学は分子生物学である.
薬理学薬理学とは

背景:

アデノシンA(2A) 受容体 (A(2A) は,様々な生理学的プロセスに関与するGタンパク質結合受容体である.
コレステロールは,GPCRを含む膜タンパク質の機能を調節することが知られている.
リンガンド受容体とコレステロールの相互作用を理解することは,薬物の発見の鍵です.

研究の目的:

アデノシンA2A受容体におけるコレステロールの特定の結合部位を調査する.
コレステロールがA(2A) R機能とリガンド結合を調節する役割を明らかにする.

主な方法:

アデノシンに結合するA(2A) 受容体の広範な分子ダイナミクス (MD) シミュレーションが行われました.
合計シミュレーション時間は1.4マイクロ秒に達しました.
分析は,コレステロールと受容体の間の安定した相互作用部位を特定することに焦点を当てました.

主要な成果:

A2A受容体の特定のコレステロール結合部位の明確な証拠が特定されました.
3つの主要な結合部位が検出されました: 2つは細胞外小葉 (ヘリックスVII/I,II/IIIと相互作用する),1つは細胞内小葉 (ヘリックスIII/IVと相互作用する).
一つの予測された結合部位は,最近発表された高解像度結晶構造によって実験的に検証された.

結論:

コレステロールは,特定の膜関連部位でアデノシンA2A受容体と直接相互作用する.
これらの相互作用は,おそらく受容体の構成と機能に影響を与える.
この発見は,コレステロールがA(2A) R薬理学における役割を理解するための構造的基礎を提供します.

さらに関連する動画

Cholesterol Efflux Assay

Cholesterol Efflux Assay

Published on: March 6, 2012

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Published on: December 19, 2025

関連する概念動画

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

Adrenergic Receptors: β Subtype

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...